These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21700507)

  • 21. Primary Gleason grade 4 impact on biochemical recurrence after permanent interstitial brachytherapy in Japanese patients with low- or intermediate-risk prostate cancer.
    Uesugi T; Saika T; Edamura K; Nose H; Kobuke M; Ebara S; Abarzua F; Katayama N; Yanai H; Nasu Y; Kumon H
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e219-23. PubMed ID: 21640517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy.
    Pickles T;
    Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1355-9. PubMed ID: 16406391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
    Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
    Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does the outcome of prostate cancer patients with large prostates differ from small prostate size in permanent seed, low dose-rate brachytherapy?
    Aaltomaa SH; Kataja VV; Räty A; Palmgren JE; Lahtinen T
    Scand J Urol Nephrol; 2011 Nov; 45(5):339-45. PubMed ID: 21767248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of hypertriglyceridemia on prostate cancer development in patients aged ≥60 years.
    Hayashi N; Matsushima M; Yamamoto T; Sasaki H; Takahashi H; Egawa S
    BJU Int; 2012 Feb; 109(4):515-9. PubMed ID: 21812901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does body mass index "dilute" the predictive property of prostate-specific antigen for tumor volume at radical prostatectomy?
    Mitchell CR; Umbreit EC; Rangel LJ; Bergstralh EJ; Karnes RJ
    Urology; 2011 Oct; 78(4):868-72. PubMed ID: 21843902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Body mass index is not a prognostic marker for prostate-specific antigen failure and survival in Dutch men treated with brachytherapy.
    van Roermund JG; Hinnen KA; Battermann JJ; Witjes JA; Bosch JL; Kiemeney LA; van Vulpen M
    BJU Int; 2010 Jan; 105(1):42-8. PubMed ID: 19519759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis.
    Horwitz EM; Levy LB; Thames HD; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Sandler HM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
    Cancer; 2006 Oct; 107(7):1496-502. PubMed ID: 16944536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer.
    Efstathiou JA; Chen MH; Renshaw AA; Loffredo MJ; D'Amico AV
    Cancer; 2007 Apr; 109(8):1493-8. PubMed ID: 17340594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erectile function status is highly associated with prostate-specific antigen bounce in localized prostate cancer patients treated with permanent prostate brachytherapy.
    Matsushima M; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Ohashi T; Mikami S; Miyajima A; Shigematsu N; Oya M
    Int J Urol; 2016 Mar; 23(3):247-52. PubMed ID: 26663514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications.
    Stock RG; Stone NN; Cesaretti JA
    Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):448-53. PubMed ID: 12738319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of metastatic disease after prostate brachytherapy.
    Forsythe K; Burri R; Stone N; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):645-52. PubMed ID: 22137025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
    Culp S; Porter M
    BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prostate-specific antigen bounce after permanent seed prostate brachytherapy: a literature review].
    Mazeron R; Bajard A; Pommier P
    Cancer Radiother; 2012 Dec; 16(8):702-10; quiz 722, 725. PubMed ID: 23177779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer.
    Ochiai A; Fritsche HA; Babaian RJ
    Urology; 2005 Oct; 66(4):819-23. PubMed ID: 16230145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isotope and patient age predict for PSA spikes after permanent prostate brachytherapy.
    Bostancic C; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath R; Lief J; Gutman SE
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1431-7. PubMed ID: 17544597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon.
    Caloglu M; Ciezki J
    Urology; 2009 Dec; 74(6):1183-90. PubMed ID: 19428077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapy.
    Fang LC; Merrick GS; Butler WM; Galbreath RW; Murray BC; Reed JL; Adamovich E; Wallner KE
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):992-6. PubMed ID: 20932674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
    Zelefsky MJ; Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Pisansky TM; Elshaikh M; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):327-33. PubMed ID: 17084558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.